CBIO
Crescent Biopharma, Inc.Health Care · ·
$16.43
▲ $0.66 (+4.2%)
Market Cap
$610.27M
Day Range
$15.73 - $16.51
52-Week Range
$8.72 - $27.41
Beta
—
Next Earnings
—
CBIO is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
🏢 Similar Stocks in the Same Sector
+49.4% (1Y)
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
🔍 Cross-Check
Overall Score
🔴 Bearish
Technical Trend
🟡 Mixed
Insiders
🔴 Bearish
✅ Why is the score relatively high?
- 🟢 Current ratio: 6.56
- 🟢 Price is above the 200-day average
- 🟢 MACD histogram is positive — rising momentum
- 🟢 RSI 51.1 — healthy positive momentum
- 🟢 Current ratio: 6.56
⚠️ What's concerning?
- 🔴 Operating margin: -1407.5% (negative)
- 🔴 Net margin: -1419.6% (negative)
- 🔴 Operating margin is eroding over time
- 🔴 ATR: 8.3% of price
- 🔴 Return on equity (ROE): -75.8% (negative)
🚦 Quality & Risk Checks
📰 News Trend
Based on real financial news (Finnhub)Everyone's writing about Crescent Biopharma, Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 0 vs. 0 out of the last 2 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
📈 Technical Analysis
Based on the last 251 trading days, calculated from real price data. Click an indicator for details and a chart.
🟡 Indicators are mixed — no clear bias (4 bullish · 5 bearish · 3 neutral)
Conclusions
- 🔴Price vs. SMA 50 — Price is below the 50-day average
- 🟢Price vs. SMA 200 — Price is above the 200-day average
- 🟢MACD — MACD histogram is positive — rising momentum
- 🟢RSI — RSI 51.1 — healthy positive momentum
- 🟡Stochastic — %K 64.0 — neutral range
- 🟡ADX (trend strength) — ADX 13.4 — weak trend/choppy
- 🔴Volume trend — Volume is falling despite the price advance — possible weakening
- 🔴Relative strength vs. S&P 500 — -13.8% over the last 3 months relative to the index
- 🟢Bollinger Bands — Price is in the upper third of the Bollinger Bands (69%B) — strong momentum (risk of a pullback)
- 🔴ROC (rate of change) — ROC 12 days: -1.3%
- 🔴Parabolic SAR — Price is below the SAR point — downtrend
- 🟡CMF (money flow) — CMF 20 days: -0.05
Wyckoff Method Analysis
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
Evidence Behind This Read
- 🔴Falling price trend — A -21.0% change over the last 50 days, with no defined trading range.
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
🎯 Trade Planning (M.A.E.E Framework)
Based on a mechanical trading method: market structure → value zone → ATR-based exit point. Not investment advice — a calculation tool only.
1️⃣ Market Structure
🟢 Uptrend
The price is above the 200-day average — per the market-structure method, this environment mainly favors looking for buying (Long) opportunities.
2️⃣ Value Zone
🟡 Price far from value zone
The price is currently far from the 50-day average — the method recommends waiting for a "pullback" before entering, rather than chasing prices.
3️⃣ Suggested Exit Point (ATR-based)
Method formula: Stop-loss = support minusone ATR margin — this way the stop adapts to the stock's actual volatility, rather than an arbitrary number.
Entry
$16.43
Stop-Loss
$12.63
Risk per Share
$3.80
Direction
Long
Profit Targets by Risk/Reward Ratio (R)
1:2 R
$24.04
1:3 R
$27.84
1:5 R
$35.45
💰 Position Size Calculator
A core principle of the method: never risk a fixed dollar amount — risk a fixed percentage of equity, and let the position size vary according to the risk per share.
Suggested Position Size
26 sh.
💰 Financial Health
Profitability
Gross Margin
—
Operating Margin
-1407.5%
Net Margin
-1419.6%
EBITDA Margin
-1407.5%
Efficiency
ROE
-75.8%
ROA
-64.1%
ROIC
—
EPS
—
Balance Sheet
Cash
$213.19M
Total Debt
—
Current Ratio
6.56
Debt/Equity
—
Conclusions
- 🔴Operating margin — Operating margin: -1407.5% (negative)
- 🔴Net margin — Net margin: -1419.6% (negative)
- 🔴Return on equity (ROE) — Return on equity (ROE): -75.8% (negative)
- 🔴Return on assets (ROA) — Return on assets (ROA): -64.1% — weak
- 🟢Current ratio (liquidity) — Current ratio: 6.56
🚀 Growth
Revenue
Earnings per Share (EPS)
Net Income
Free Cash Flow (FCF)
Conclusions
- 🔴Free cash flow growth — Free cash flow growth: -132.9%
- 🔴Net income growth — Net income growth: -306.4%
💵 Dividends
Total dividend per share paid each year, over the last 5 years.
Annual Dividend per Share
| Ex-Dividend Date | Amount per Share |
|---|---|
| 13.1.2023 | $24.000 |
| 21.9.2022 | $143.000 |
💎 Fair Value (Valuation)
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
—
Tangible Book Value per Share (Tangible NAV)
—
Conclusions
Not enough data to compute signals.
🕴️ Insider Trading
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 7 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Open Market Purchase | 16.7.2026 | 3,601,316 | +853,450 | $14.50 |
| Fairmount Funds Management LLC | Open Market Purchase | 16.7.2026 | 2,294,037 | +525,897 | $14.50 |
| Brumm Joshua T | Open Market Sale | 22.6.2026 | 281,212 | -42,305 | $17.99 |
| McNeill Jonathan | Open Market Sale | 22.6.2026 | 139,158 | -20,549 | $17.99 |
| Im Ellie Eunkyung | Open Market Sale | 22.6.2026 | 22,069 | -1,219 | $17.99 |
| Bispham Barbara Harlin | Open Market Sale | 22.6.2026 | 19,330 | -1,218 | $17.99 |
| Scalzo Richard William | Open Market Sale | 22.6.2026 | 20,298 | -1,112 | $17.99 |
| Pinkas Jan | Open Market Sale | 22.6.2026 | 22,239 | -1,288 | $17.99 |
| Lynch Ryan | Open Market Sale | 22.6.2026 | 13,871 | -465 | $17.99 |
| Fairmount Healthcare Fund II L.P. | Grant/Award from Employer | 2.6.2026 | 11,050 | +11,050 | — |
| Moran Susan | Grant/Award from Employer | 2.6.2026 | 11,050 | +11,050 | — |
| Balcom Alexandra | Grant/Award from Employer | 2.6.2026 | 11,050 | +11,050 | — |
| Lubner David Charles | Grant/Award from Employer | 2.6.2026 | 11,050 | +11,050 | — |
| Violin Jonathan | Grant/Award from Employer | 2.6.2026 | 11,050 | +11,050 | — |
| Bispham Barbara Harlin | Grant/Award from Employer | 15.12.2025 | 12,422 | +12,422 | — |
| Bispham Barbara Harlin | Grant/Award from Employer | 15.12.2025 | 18,422 | +6,000 | — |
| Bispham Barbara Harlin | Grant/Award from Employer | 15.12.2025 | 72,185 | +72,185 | — |
| Lynch Ryan | Grant/Award from Employer | 15.12.2025 | 8,378 | +8,378 | — |
| Lynch Ryan | Grant/Award from Employer | 15.12.2025 | 12,378 | +4,000 | — |
| Lynch Ryan | Grant/Award from Employer | 15.12.2025 | 33,512 | +33,512 | — |
| Im Ellie Eunkyung | Grant/Award from Employer | 15.12.2025 | 16,298 | +16,298 | — |
| Im Ellie Eunkyung | Grant/Award from Employer | 15.12.2025 | 21,298 | +5,000 | — |
| Im Ellie Eunkyung | Grant/Award from Employer | 15.12.2025 | 65,190 | +65,190 | — |
| McNeill Jonathan | Grant/Award from Employer | 15.12.2025 | 153,707 | +19,507 | — |
| McNeill Jonathan | Grant/Award from Employer | 15.12.2025 | 159,707 | +6,000 | — |
📉 Short Interest
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
Monthly Trend — Open Short Interest
3,743,278 shares short as of 2026-07-15 · vs. 3,673,343 on 2026-06-30
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
Weekly Trend — Daily Short-Sale Activity
44.7% of trading volume this week was short selling, vs. 53.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
📰 News & Sentiment
Sentiment based on basic keywords (not AI) — 0 positive, 2 neutral, 0 negative out of the last 2 articles.
Benzinga · 30.7.2026
Benzinga · 14.7.2026